2020
DOI: 10.1371/journal.pone.0237603
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%

Abstract: Background/Purpose To date, studies examining polymicrobial infections in ocular disease have mostly been limited to keratitis or endophthalmitis. We characterized polybacterial infections compared to monobacterial infections in prior clinical studies evaluating besifloxacin ophthalmic suspension 0.6% for the treatment of bacterial conjunctivitis and report on associated microbiological outcomes.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
10
1
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(13 citation statements)
references
References 62 publications
1
10
1
1
Order By: Relevance
“…Gatifloxacin is administered for ophthalmic use only after the withdrawal from systemic use due to its side effects (hypo- and hyperglycemia) [ 43 , 108 , 109 ]. The approved pharmaceutical formulation of besifloxacin is an ophthalmic suspension 0.6%, which contains 6.63 mg of besifloxacin hydrochloride (equivalent to 6 mg of besifloxacin) [ 46 , 95 , 96 , 97 , 107 ]. At present, attempts are being made to develop several ophthalmic pharmaceutical formulas with besifloxacin, such as nanoemulsions [ 110 ], positively charged liposomes [ 111 ], and for the treatment of bacterial keratitis new loaded nanofibrous ocular inserts [ 112 ].…”
Section: Compounds In Therapy Since 2000mentioning
confidence: 99%
“…Gatifloxacin is administered for ophthalmic use only after the withdrawal from systemic use due to its side effects (hypo- and hyperglycemia) [ 43 , 108 , 109 ]. The approved pharmaceutical formulation of besifloxacin is an ophthalmic suspension 0.6%, which contains 6.63 mg of besifloxacin hydrochloride (equivalent to 6 mg of besifloxacin) [ 46 , 95 , 96 , 97 , 107 ]. At present, attempts are being made to develop several ophthalmic pharmaceutical formulas with besifloxacin, such as nanoemulsions [ 110 ], positively charged liposomes [ 111 ], and for the treatment of bacterial keratitis new loaded nanofibrous ocular inserts [ 112 ].…”
Section: Compounds In Therapy Since 2000mentioning
confidence: 99%
“…Staphylococcal species including Staphylococcus aureus (SA) and Staphylococcus epidermidis (SE) are among the most common bacterial pathogens involved in the aetiology of acute conjunctivitis [1].…”
Section: Introductionmentioning
confidence: 99%
“…Staphylococcal species including Staphylococcus aureus (SA) and Staphylococcus epidermidis (SE) are among the most common bacterial pathogens involved in the etiology of acute conjunctivitis [1].…”
Section: Introductionmentioning
confidence: 99%
“…Staphylococcal species including Staphylococcus aureus (SA) and Staphylococcus epidermidis (SE) are among the most common bacterial pathogens involved in the etiology of acute conjunctivitis [1]. Important aspects of pathogenic potential of staphylococci linked to their ability to cause conjunctivitis include initial adherence, inherent virulence, cytotoxicity, as well as evasion of the host immune system and antimicrobial tolerance/resistance facilitated by the bio lm production [2,3,4].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation